Israel · Delayed Price · Currency is ILS · Price in ILA Can-Fite BioPharma Earnings Call Transcripts
Fiscal Year 2024
-
Multiple late-stage clinical programs are advancing, including pivotal phase III trials for psoriasis and liver cancer, and a new phase IIa trial in pancreatic cancer. Strategic partnerships and licensing deals have generated significant revenue, with strong market opportunities ahead.
-
Recent funding and milestone payments provide 16-18 months of runway, with additional non-dilutive deals in progress. Lead drugs are advancing in pivotal trials for psoriasis and liver cancer, with strong safety and efficacy profiles, and multiple out-licensing agreements support future growth.
-
Multiple late-stage clinical programs are advancing, with pivotal studies in liver cancer and psoriasis set to begin. $20 million has been secured from licensing, with potential for $130 million more, targeting multi-billion-dollar markets and further milestones in 2024.
-
Advancing two lead oral drug candidates in pivotal phase III trials for psoriasis and liver cancer, with strong safety profiles and regulatory alignment. Multiple licensing deals and a robust IP portfolio support financial stability and future growth.
-
Two pivotal phase III trials are underway for psoriasis and liver cancer, with interim analyses planned that could enable conditional approval. Multiple out-licensing deals and a strong cash position support ongoing development, while new partnerships and non-dilutive funding are being pursued.